

# JAKE K. KLAISNER

FSA, MAAA

Principal and Consulting Actuary

jake.klaisner@milliman.com

Main +1 262 784 2250 | Office +1 262 923 3652



## Current Responsibility

Jake Klaisner is a principal and consulting actuary with the Milwaukee office of Milliman. He joined the firm in 2013.

## Professional Work Experience

Jake has over a decade of healthcare experience in managed care pricing, financial reporting, strategic analysis, regulatory analysis, and compliance. His areas of expertise include Medicare Part D, prescription drug analytics, and pharmaceutical manufacturer market access strategy. In the Medicare market, Jake has assisted Medicare Part D plans with bid preparation and strategic analyses. He also conducts firm-wide research in formulary analytics, PDP market dynamics, and Part D risk score analysis. He is a key contributor to Milliman's Part D research efforts. In the pharmacy space, Jake has worked with pharmaceutical manufacturers, industry organizations, and government entities, with emphasis on the Medicare Part D benefit. His recent work includes helping clients with payment strategy, market access, and regulatory issues.

## Professional Designations

- Fellow, Society of Actuaries
- Member, Academy of Actuaries

## Education

BBA, Actuarial Science, Risk Management and Insurance, and Economics, University of Wisconsin

## Presentations and Publications

Publications:

- Co-Author, Direct-to-patient Prescription Drugs: A framework to help pharmaceutical manufacturers evaluate their strategy. Milliman White Paper, March 2026.
- Co-Author, Medicare drug price negotiation: New dynamics as the tide turns to Medicare Part B. Maximum Fair Price Issue, January 2026.
- Co-Author, Medicare drug price negotiation: Navigating the next wave of maximum fair prices. Maximum Fair Price Issue, January 2026.

- Co-Author, Variations in Outpatient Hospital Reimbursement for Autoimmune Drugs. An Analysis of Hospital Price Transparency Data. Report, December 2025.
- Co-Author, Continued concentration and sustained stabilization: A 2026 Medicare prescription drug plan market overview. Milliman White Paper, October 2025.
- Co-Author, Analysis of Commercial and Medicare Outpatient Drug Spend at 340B Participating Hospitals. Report, July 2025.
- Co-Author, Medicare Price Negotiation: Year 2 Selection Expands to New Therapeutic Areas. Milliman White Paper, February 2025.
- Co-Author, Demonstrations and consolidations: A first view of the 2025 PDP market. Milliman White Paper, October 2024.
- Co-Author, Medicare price negotiation: Anchored drug prices in uncharted waters. Milliman White Paper, September 2024.
- Co-Author, Impact of anti-obesity medication coverage in the Medicaid and commercial markets. Client Report, June 2024.
- Co-Author, Impact of anti-obesity medication coverage in Medicare Part D. Client Report, June 2024.
- Co-Author, Low income disruption and the \$0 premium introduction: 2024 individual Medicare PDP market turbulence. Milliman White Paper, October 2025.

Presentations:

- Charting the IRA's Drug Price Negotiation: Navigating the Waters of Stakeholder Impacts. SOA webinar, November 2023.
- Anti-Obesity Medication Coverage and Management, Digital Health New York – Obesity Work Group, October 2023.
- Capitalizing on Uncertainty: Winning Strategies with the Inflation Reduction Act. SOA Health Meeting, June 2023.
- Post-IRA Reality and A Way Forward, No Patient Left Behind webinar, September 2022.
- The Inflation Reduction Act: What's changing in healthcare? Milliman webinar, August 2022.
- Hot Topics Roundtable: Changes in Part D and Part B Drugs – Minimizing Risks and Costs, RISE – Part D Master Class, August 2022.